An FDA warning letter posted September 15, 2026 cites sterile-drug current good manufacturing practice violations at Bausch & Lomb’s Tampa facility. The letter signals potential patient-safety concerns and legal exposure if manufacturing deficiencies are not corrected. This is distinct from billing and fraud matters because it involves drug-manufacturing compliance under FDA regulatory authority.
